Projektbeschreibung
KI steuert Behandlung der Sichelzellenkrankheit
Die Sichelzellkrankheit ist eine genetische Störung, die die Funktion der roten Blutkörperchen beeinträchtigt, womit eine Störung der Sauerstoffversorgung aller Organe einhergeht. Obwohl es einige wirksame Behandlungen gibt, die die Krankheitssymptome lindern, ist die Entscheidungsfindung schwierig und wird nur unzureichend unterstützt. Ziel des EU-finanzierten Projekts INNOVHEM ist es, die klinische Versorgung der von der Sichelzellkrankheit Betroffenen zu verbessern und ihre Lebensqualität zu erhöhen. Dazu entwickeln die Forschenden eine Lösung mit künstlicher Intelligenz (KI), die biologische und klinische Parameter der Krankheit berücksichtigt, um medizinischem Personal bei der Erstellung eines personalisierten Behandlungsplans zu helfen.
Ziel
INNOVHEM is a french start-up that has been incorporated in October 2019 which develops new and relevant diagnostic tools to tackle Sickle cell disease. Sickle Cell Disease is a very severe disease and is the most frequent genetic disease over the world, affecting around 5 million people. Despite this disease has been discovered at the beginning of the 20th century, there is still several unmet needs to tackle it.
In resource-poor countries, about 90% of children are estimated to die before the age of 5. In Europe, more than 60 000 people are affected. Their life expectency is shortened to around 45 years old and 80% of physicians say that they lack support tools for treatment decision. In addition, SCD is associated to high clinical costs. At INNOVHEM, we are developing a solution which is a combination of biomarkers, specifically adapted to the physiopathology of the disease, with articial intelligence. This solution will help the physicians to propose a personalized medical care to the patients and it will also help the development of new effective treatments. This will deeply improve health of Sickle cell patients. As an example of impacts, one of the short-term goals is to avoid 20% of emergency visits, this sole effect will save $ 30 million / year in Europe.
During the first year of activity, INNOVHEM showed a high commercial traction, that allows to sign contracts for a total amonut of 800k euros . We also enter into several partnerships with leading clinical and university centers for sickle cell disease.
Our mission is to improve clinical care of Sickle cell patients and improve their lives. A financial support will help us to build our access market strategy and our growth in Europe.
Schlüsselbegriffe
Programm/Programme
- HORIZON.3.2 - European innovation ecosystems Main Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
(öffnet in neuem Fenster) HORIZON-EIE-2021-SCALEUP-01
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
HORIZON-CSA -Koordinator
91000 Evry-Courcouronnes
Frankreich